http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113876780-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24a5f6d4a1647b5999d9b8897c09ec61 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2021-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc501e7863b62de698379f57024b8c4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_256de1d049bf9d3788ea9c3dae36e07e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_349a3b70d3e7fe00575bc9d8aeed8cf2 |
| publicationDate | 2022-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113876780-A |
| titleOfInvention | A pharmaceutical composition and its application in preparing a medicine for treating non-small cell lung cancer |
| abstract | The invention discloses a pharmaceutical composition and its application in preparing a medicine for treating non-small cell lung cancer. The pharmaceutical active ingredients of the pharmaceutical composition include a first component and a second component, wherein the first component It is gefitinib, the second component is compound A with the structure shown in general formula (I), compound A can enhance the inhibitory ability of gefitinib on the activity, invasion and migration of EGFR-mutated NSCLC cells, and Enhance the ability of gefitinib to promote apoptosis of EGFR-mutated NSCLC cells. The combined use of compound A and gefitinib effectively expands the application scope of gefitinib and improves NSCLC patients' ability to respond to gefitinib. It is beneficial to improve the therapeutic effect of gefitinib on NSCLC patients, and has important value for the clinical application of gefitinib in the treatment of NSCLC. |
| priorityDate | 2021-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.